GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (NAS:BPMC) » Definitions » Cyclically Adjusted Price-to-FCF

Blueprint Medicines (Blueprint Medicines) Cyclically Adjusted Price-to-FCF : (As of May. 15, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Blueprint Medicines Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Blueprint Medicines's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Cyclically Adjusted Price-to-FCF Chart

Blueprint Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Blueprint Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Blueprint Medicines's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Blueprint Medicines's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Cyclically Adjusted Price-to-FCF falls into.



Blueprint Medicines Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Blueprint Medicines's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Blueprint Medicines's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.608/129.4194*129.4194
=-1.608

Current CPI (Mar. 2024) = 129.4194.

Blueprint Medicines Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.662 100.560 -0.852
201409 -0.669 100.428 -0.862
201412 -0.916 99.070 -1.197
201503 0.196 99.621 0.255
201506 -0.664 100.684 -0.854
201509 -0.495 100.392 -0.638
201512 -0.621 99.792 -0.805
201603 1.089 100.470 1.403
201606 -0.677 101.688 -0.862
201609 -0.703 101.861 -0.893
201612 -0.661 101.863 -0.840
201703 -0.943 102.862 -1.186
201706 -0.716 103.349 -0.897
201709 -0.792 104.136 -0.984
201712 -1.133 104.011 -1.410
201803 -1.279 105.290 -1.572
201806 -0.141 106.317 -0.172
201809 -1.312 106.507 -1.594
201812 -1.546 105.998 -1.888
201903 -1.859 107.251 -2.243
201906 -1.707 108.070 -2.044
201909 -1.592 108.329 -1.902
201912 -0.991 108.420 -1.183
202003 -2.105 108.902 -2.502
202006 -1.883 108.767 -2.241
202009 10.959 109.815 12.915
202012 -0.438 109.897 -0.516
202103 -2.171 111.754 -2.514
202106 -1.093 114.631 -1.234
202109 -1.647 115.734 -1.842
202112 -4.637 117.630 -5.102
202203 -2.257 121.301 -2.408
202206 -2.026 125.017 -2.097
202209 -2.236 125.227 -2.311
202212 -2.052 125.222 -2.121
202303 -2.088 127.348 -2.122
202306 -2.198 128.729 -2.210
202309 -1.825 129.860 -1.819
202312 -1.373 129.419 -1.373
202403 -1.608 129.419 -1.608

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Blueprint Medicines  (NAS:BPMC) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Blueprint Medicines Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines (Blueprint Medicines) Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
Executives
Ariel Hurley officer: Principal Accounting Officer C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Jeffrey W. Albers director, officer: CEO & President BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Christopher K. Murray officer: SVP, Technical Operations C/O BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Fouad Namouni officer: President, R and D 535 BOYLSTON ST., 2ND FLOOR, BOSTON MA 02116
L. Becker Hewes officer: Chief Medical Officer C/O BLUEPRINT MEDICINES, CORPORATION, CAMBRIDGE MA 02139
Percy H. Carter officer: Chief Scientific Officer C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Philina Lee officer: Chief Commercial Officer C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Christina Rossi officer: Chief Commercial Officer 45 SIDNEY STREET, BLUEPRINT MEDICINES CORPORATION, CAMBRIDGE MA 02139
Tracey L Mccain officer: EVP and Chief Legal Officer C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Michael Landsittel officer: Principal FAO BLUEPRINT MEDICINES CORP., 214 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Debra Durso-bumpus officer: Chief People Officer C/O BLUEPRINT MEDICINES CORORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Kate Haviland officer: Chief Business Officer BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
John Tsai director BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
George Demetri director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142